IL-STERN-PINBALL-INC
22.9.2022 16:01:41 CEST | Business Wire | Press release
Stern Pinball, Inc. launches a new line of pinball machines celebrating the iconic, genre-defining James Bond films. The James Bond 007 cornerstone series features the original 007 actor, Sean Connery, available in Pro Edition, Premium Edition, and Limited Edition (LE). Stern Pinball will also release a special James Bond 007 60th Anniversary Limited Edition pinball machine featuring all six James Bond actors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005077/en/
James Bond 007 Pinball Pro Edition (Photo: Business Wire)
In Dr. No (1962) Sean Connery propelled 007 into the cultural zeitgeist, bringing the legendary literary figure to life through adrenalized action sequences, ground-breaking gadgets and effects, memorable characters, and timeless villains.
Stern’s James Bond 007 cornerstone pinball machine will highlight film footage and iconic music from the films that built the 007 legend: Dr. No, From Russia With Love (1963), Goldfinger (1964), Thunderball (1965), You Only Live Twice (1967), and Diamonds Are Forever (1971). Players are immersed into the world of espionage in this action-packed pinball experience, tackling assignments, teaming up with key allies, and stopping SPECTRE’s villainous schemes.
Gather gadgets from Q Branch as pinballs get ejected through the roof of a custom sculpted Aston Martin DB5. Break through the Osato Chemicals drop targets to battle SPECTRE at the Bird 1 rocket base. And hold your breath on the gravity defying, magnetic jetpack as it transports pinballs across the playfield.
James Bond 007 pinball machines include Stern’s award-winning Insider Connected™ system, which enables players to interact with the game and a global network of players in a variety of ways. Through Insider Connected, players can track progress, earn new game-specific achievements, engage with the player community, and participate in promotions and Challenge Quests. Insider Connected also provides an operator-focused toolset to drive location play through Location Leaderboards, build player loyalty, analyze performance, make adjustments remotely, and maintain the machines. Registration for Insider Connected is available at insider.sternpinball.com/.
Limited to 1,000 machines globally, the highly collectible cornerstone Limited Edition includes an exclusive full-color mirrored backglass inspired by Thunderball, masterfully adapted cabinet artwork, custom high gloss and powder-coated pinball armor, a custom designer-autographed bottom arch, exclusive inside art blades, upgraded audio system, anti-reflection pinball playfield glass, shaker motor, a sequentially numbered plaque, and a Certificate of Authenticity signed by Stern Chairman Gary Stern and President Seth Davis.
Stern’s James Bond 007 60th Anniversary Limited Edition pinball machines will immerse players in the history of 007. Limited to 500 machines globally, the highly collectible 60th Anniversary Limited Edition offers players a retro-inspired playfield packed with exciting mechanical action. Control the chaos from Oddjob’s kinetic spinning disc hat, survive tactical precision shots against 10 drop targets, escape SPECTRE’s evil henchmen navigating pinballs through 4 fast-flowing optical spinners, learn assignments through an in-playfield LCD screen, and rack up high scores on classic-style score reels.
“James Bond is as timeless as pinball. Partnering with EON Productions/Danjaq, MGM Studios and Aston Martin, we created a pinball adventure capturing the suspense, action, and humor from this beloved film series,” said Gary Stern, Chairman and CEO. “Get connected today and become a legend.”
Fittingly, the new James Bond 007 pinball machines will be on show for the first time to media and public in London. On September 26th the games will be on display and available to play as part of the Bond-themed Christie’s Late, a public event celebrating the forthcoming Christie’s Sixty Years of James Bond Charity Auction. Shortly after, they will be a part of the James Bond at 60 weekend at the British Film Institute on the South Bank, September 30th-October 2nd.
Pricing and Availability:
Manufacturer’s Suggested Retail Price (“MSRP”)*:
*MSRP for sales to USA end-users, before any VAT, GST, Sales Tax, Duties, or other taxes.
Pro Edition: $US 6,999
Premium Edition: $US 9,699
Limited Edition: $US 12,999
60th Anniversary Limited Edition: CALL FOR PRICE
James Bond 007 pinball machines and accessories are available now through authorized Stern Pinball distributors and dealers around the world. Pro and Premium Editions will also be available at 007Store.com.
About Stern Pinball, Inc.
Stern Pinball, Inc. is a global lifestyle brand based on the iconic and outrageously fun modern American game of pinball. Headquartered minutes from Chicago’s O’Hare International Airport in the heart of North America, the company creates, designs, engineers, manufactures, markets, and distributes a full line of technologically advanced terrestrial and digital pinball games, parts, accessories, and merchandise. Stern Pinball serves digital, consumer, commercial, and corporate markets around the globe.
Recent Stern Pinball titles include Rush, Godzilla, The Mandalorian, Led Zeppelin, Avengers: Infinity Quest, Teenage Mutant Ninja Turtles, Stranger Things, Elvira’s House of Horrors, Jurassic Park, Black Knight: Sword of Rage, The Munsters, The Beatles, Deadpool, Iron Maiden, Guardians of the Galaxy, Star Wars, Aerosmith, Ghostbusters, KISS, Metallica, Game of Thrones, The Walking Dead, Star Trek, AC/DC, Batman, and Spider-Man. A broad range of players enjoy Stern Pinball’s games from professional pinball players who compete in high-stakes competitions around the globe to novice players who are discovering the allure of the silver ball for the first time. To join the fun and learn more, please visit www.sternpinball.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom